38 results match your criteria: "CRF Skirball Center for Innovation[Affiliation]"
Circ Cardiovasc Interv
July 2017
From the CRF-Skirball Center for Innovation, Orangeburg, NY (Y.C., P.G., J.-G.X., J.C.M., G.B.C., G.L.K., J.F.G.); Amaranth Medical, Inc, Mountain View, CA (K.R., C.L., E.A.E., D.D.); 3rd Department of Cardiology, Medical University of Silesia, Katowice, Poland (P.G.); and Cardiovascular Research Foundation, New York, NY (T.M.).
Background: Mechanical strength of bioresorbable scaffolds (BRS) is highly dependent on strut dimensions and polymer features. To date, the successful development of thin-walled BRS has been challenging. We compared the biomechanical behavior and vascular healing profile of a novel thin-walled (115 µm) sirolimus-eluting ultrahigh molecular weight amorphous poly-l-lactic acid-based BRS (APTITUDE, Amaranth Medical [AMA]) to Absorb (bioresorbable vascular scaffold [BVS]) using different experimental models.
View Article and Find Full Text PDFOpen Heart
May 2017
Skirball Center for Cardiovascular Research, Cardiovascular Research Foundation, Orangeburg, New York, USA.
Objective: To evaluate the biological effect of microengineered stent grooves (MSG) on early strut healing in humans by performing optical coherence tomography (OCT) analysis 3 weeks following the implantation.
Background: In the experimental setting, MSG accelerate endothelial cell migration and reduce neointimal proliferation compared with bare metal stent (BMS).
Methods: A total of 37 patients undergoing percutaneous coronary intervention with de novo coronary lesions were randomly assigned to either MSG (n=19) or an identical BMS controls (n=18).
Circ Cardiovasc Interv
May 2017
From the CRF-Skirball Center for Innovation, Orangeburg, NY (P.G., Y.C., A.F.V., J.M., G.B.C., G.L.K., J.F.G.); and Third Department of Cardiology, Medical University of Silesia, Katowice, Poland (P.G.).
Background: A polymer-free peripheral paclitaxel-eluting stent (PES, Zilver PTX, Cook, IN) has shown to improve vessel patency after superficial femoral angioplasty. A new-generation fluoropolymer-based PES (FP-PES; Eluvia, Boston Scientific, MA) displaying more controlled and sustained paclitaxel delivery promise to improve the clinical outcomes of first-generation PES. We sought to compare the biological effect of paclitaxel delivered by 2 different stent-coating technologies (fluoropolymer-based versus polymer-free) on neointimal proliferation and healing response in the familial hypercholesterolemic swine model of femoral restenosis.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
February 2018
CRF-Skirball Center for Innovation, Orangeburg, New York.
Objectives: The aim of the study was to evaluate the biomechanical properties and healing pattern of novel sirolimus-eluting, ultrahigh molecular weight amorphous poly-L-lactic acid bioresorbable scaffolds (S-BRS) that have been postdilated by 0.55 and 0.8 mm beyond the nominal diameters within the pressure-diameter compliance chart range.
View Article and Find Full Text PDFEuroIntervention
June 2017
CRF Skirball Center for Innovation, Cardiovascular Research Foundation, Orangeburg, NY, USA.
Aims: The Mitra-Spacer (Cardiosolutions, Bridgewater, MA, USA) is designed to treat mitral regurgitation by introducing a dynamic spacer that constantly adapts to the changing haemodynamic conditions during the cardiac cycle. We aimed to evaluate the performance and safety of this device in the chronic ovine model.
Methods And Results: Eight sheep were enrolled in this study.
Aims: The vascular healing profile of polymers used in bioresorbable vascular scaffolds (BRS) has not been fully characterised in the absence of antiproliferative drugs. In this study, we aimed to compare the polymer biocompatibility profile and vascular healing response of a novel ultrahigh molecular weight amorphous PLLA BRS (FORTITUDE®; Amaranth Medical, Mountain View, CA, USA) against bare metal stent (BMS) controls in porcine coronary arteries.
Methods And Results: Following device implantation, optical coherence tomography (OCT) evaluation was performed at 0 and 28 days, and at one, two, three and four years.
Aims: The aim of this study was to evaluate the biological efficacy of a novel lower-dose (2.5 µg/mm2) encapsulated paclitaxel nanocrystal-coated balloon (Nano-PCB) in the familial hypercholesterolaemic swine (FHS) model of iliofemoral in-stent restenosis.
Methods And Results: Nano-PCB pharmacokinetics were assessed in 20 femoral arteries (domestic swine).
Circ Cardiovasc Interv
October 2016
From the CRF-Skirball Center for Innovation, Orangeburg, NY (Y.C., P.G., M.S., J.C.M., G.B.C., G.L.K., J.F.G.); Amaranth Medical, Inc, Mountain View, CA (K.R., C.L., E.A.E., D.D.); and 3rd Department of Cardiology, Medical University of Silesia, Katowice, Poland (P.G.).
Background: Clinically available bioresorbable scaffolds (BRS) rely on polymer crystallinity to achieve mechanical strength resulting in limited overexpansion capabilities and structural integrity when exposed to high-loading conditions. We aimed to evaluate the biomechanical behavior and vascular healing profile of a novel, sirolimus-eluting, high-molecular-weight, amorphous poly-l-lactic acid-based BRS (Amaranth BRS).
Methods And Results: In vitro biomechanical testing was performed under static and cyclic conditions.
JACC Cardiovasc Imaging
August 2016
Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Medical Biochemistry, Academic Medical Center, Amsterdam, the Netherlands. Electronic address:
Objectives: The goal of this study was to develop and validate a noninvasive imaging tool to visualize the in vivo behavior of high-density lipoprotein (HDL) by using positron emission tomography (PET), with an emphasis on its plaque-targeting abilities.
Background: HDL is a natural nanoparticle that interacts with atherosclerotic plaque macrophages to facilitate reverse cholesterol transport. HDL-cholesterol concentration in blood is inversely associated with risk of coronary heart disease and remains one of the strongest independent predictors of incident cardiovascular events.
Med Phys
March 2016
Interventional Cardiology, Mt. Sinai Medical Center, New York, New York 10029.
Purpose: This paper reports the first results obtained using a novel technology called eye controlled region of interest (ECR) that substantially reduces both staff and patient irradiation during an interventional fluoroscopy procedure without interfering with workflow. Its collimator includes a partially x-ray attenuating plate with a nonattenuating aperture. An eye tracker follows the operator's gaze to automatically position the aperture to the clinical region of interest (CROI) anywhere in the image in real-time.
View Article and Find Full Text PDFExpert Opin Drug Deliv
June 2016
a CRF-Skirball Center for Innovation, Orangeburg , NY , USA.
Introduction: Drug-coated balloons (DCB) promise to deliver anti-proliferative drugs and prevent restenosis leaving nothing behind. Although, randomized clinical trials have demonstrated their efficacy for the treatment of in-stent restenosis, clinical evidence supporting their use in other coronary applications is still lacking.
Areas Covered: This review summarizes the development status of clinically available DCB technologies and provides an update on the current data for their coronary use.
EuroIntervention
August 2016
CRF-Skirball Center for Innovation, Orangeburg, New York, NY, USA.
Aims: Among antirestenotic compounds, sirolimus displays a superior safety profile compared to paclitaxel, but its pharmacokinetic properties make it a challenging therapeutic candidate for single-time delivery. Herein we evaluate the feasibility of delivery, long-term retention and vascular effects of sirolimus nanoparticles delivered through a novel porous angioplasty balloon in normal porcine arteries and in a swine model of in-stent restenosis (ISR).
Methods And Results: Sirolimus nanoparticle formulation was delivered via porous balloon angioplasty to 753 coronary artery segments for pharmacokinetic studies and 26 segments for biological effect of sirolimus delivery in different clinical scenarios (de novo [n=8], ISR [n=6] and following stent implantation [n=12]).
EuroIntervention
April 2015
CRF Skirball Center for Innovation, Cardiovascular Research Foundation, Orangeburg, NY, USA.
Aims: To test the feasibility of a thoracoscopically assisted, off-pump, transcatheter ventricular reconstruction (TCVR) approach in an ovine model of left ventricular (LV) anteroapical aneurysm.
Methods And Results: Myocardial infarction (MI) was induced by coil occlusion of the middle left anterior descending artery and diagonals. Two months after MI creation, TCVR was performed via a minimal thoracotomy in eight sheep.